Deals: Page 2


  • Image attribution tooltip
    Getty Images

    Acceleron provides biggest biopharma deal this year, with $11.5B sale to Merck

    The acquisition is notable for Merck, which is under pressure to diversify its business beyond the cancer drug Keytruda and has typically favored smaller buyouts of earlier-stage companies.

    By Updated Sept. 30, 2021
  • Image attribution tooltip
    Getty / Edited by BioPharma Dive

    Amicus, looking for a boost, sells its gene therapy work to a SPAC

    The value of the biotech's growing gene therapy portfolio has been "unrecognized" by investors, said CEO John Crowley, leading to a sudden shift for an initiative that began just three years ago.

    By Sept. 29, 2021
  • Image attribution tooltip
    Christopher Furlong via Getty Images

    AstraZeneca to buy rare disease drugmaker Caelum in small deal

    The British pharma inherited an option to acquire Caelum Biosciences when it bought Alexion last year. Caelum could receive as much as $500 million as a result of the planned buyout.

    By Kristin Jensen • Sept. 29, 2021
  • Image attribution tooltip
    AbbVie

    AbbVie bets big on a gene therapy for eye diseases

    The company has agreed to pay $370 million, and possibly north of $1 billion more, to gain access to a Regenxbio treatment targeting wet AMD and other eye conditions.

    By Sept. 13, 2021
  • Image attribution tooltip
    Courtesy of Sanofi

    Sanofi to buy Kadmon for $1.9B, extending deal streak

    The acquisition took some analysts by surprise as Sanofi has recently targeted specialty drugs, not general medicines like Kadmon's transplant treatment.

    By Sept. 8, 2021
  • Image attribution tooltip
    Roche

    Roche bets big on off-the-shelf cancer cell therapy with Adaptimmune deal

    Long a bystander in the race to develop so-called allogeneic treatments, the cancer drugmaking giant has joined the fray with a wide-ranging alliance that could be worth up to $3 billion.

    By Sept. 7, 2021
  • Lilly puts more money into protein degradation

    The pharma has struck its second research pact focused on drugs that break down harmful proteins in as many years, this time with California biotech Lycia Therapeutics. 

    By Aug. 25, 2021
  • Image attribution tooltip
    Jeenah Moon via Getty Images

    Pfizer stocks cancer drug pipeline with $2.3B deal for Trillium

    The acquisition reflects growing industry interest in the cancer-linked protein targeted by Trillium's drugs, most notably shown by Gilead's acquisition of Forty Seven last year.

    By Aug. 23, 2021
  • Illumina closes Grail takeover despite pending FTC trial

    The testing giant's decision to move ahead without sign-off from U.S. regulators and an EU investigation ongoing is a "maverick move," said Evercore analysts, as there's a chance Illumina may have to unwind the takeover.

    By Nick Paul Taylor • Aug. 19, 2021
  • Image attribution tooltip
    Adeline Kon/BioPharma Dive
    Deep Dive

    Biotech M&A, while far from recent heights, is picking back up. Here are the latest deals.

    Acquisitions haven't come close to the record levels seen just a couple years ago. But dealmaking experts foresee a turnaround in 2022, given that big-name buyers like Pfizer and Novartis are flush with cash.

    By , Updated Dec. 22, 2021
  • Image attribution tooltip
    Bayer AG

    How Bayer lured a biotech away from an IPO and into a buyout

    Vividion Therapeutics was headed toward an IPO earlier this year, but the company's co-founder said Bayer’s $1.5 billion offer ended up being a more attractive option.

    By Aug. 5, 2021
  • Image attribution tooltip
    Courtesy of Sanofi

    Sanofi bets $3.2B on mRNA with deal to buy Translate Bio

    The acquisition is a sign of how more and more large pharmaceutical companies view messenger RNA as an essential drugmaking technology. 

    By Aug. 3, 2021
  • Bluebird preps for split by selling manufacturing plant to well-funded startup

    The startup manufacturing specialist National Resilience, which raised $800 million when it launched last year, will pay Bluebird $110 million for the North Carolina facility, bringing its North American network up to 10.

    By Kristin Jensen • July 29, 2021
  • Image attribution tooltip
    Amgen Inc.

    Amgen pays $900M for Teneobio and bets bigger on next-gen antibody drugs

    The acquisition is the third Amgen has made since March and broadens its ability to develop bispecific antibodies, a drug class of intense interest to big biotech. 

    By July 28, 2021
  • Image attribution tooltip
    Elizabeth Regan / Industry Dive

    An AstraZeneca spinout scores a buyout option from Arena

    The potential acquisition marks a fast turnaround for Aristea, one of several biotechs formed from programs AstraZeneca decided not to advance internally.  

    By July 27, 2021
  • Image attribution tooltip
    Justin Sullivan via Getty Images

    Regeneron, AstraZeneca team up on targeted drugs for obesity

    After screening 650,000 people, Regeneron unearthed a mutation associated with lower weight. AstraZeneca aims to help the biotech make a drug based on its findings.  

    By July 27, 2021
  • Image attribution tooltip
    Christopher Furlong via Getty Images

    AstraZeneca deal for Alexion to close soon as UK regulator clears acquisition

    The go-ahead from British regulators was the last hurdle standing in the way of the two companies wrapping up their $39 billion deal announced last year.

    By Kristin Jensen • July 14, 2021
  • Lilly wagers up to $1B on a biotech's plan for a new type of insulin

    Rival Novo Nordisk has jumped ahead in developing an injectable drug that responds to changes in blood sugar. An acquisition of Protomer Therapeutics could help Lilly close the gap.

    By July 14, 2021
  • Image attribution tooltip
    Permission granted by Biogen

    Biogen chases rivals with another bet on emerging class of multiple sclerosis drugs

    A deal with Innocare gives Biogen a second therapy for MS that targets a protein called BTK, an approach several other competing drugmakers are pursuing, too.

    By Updated July 14, 2021
  • Image attribution tooltip
    Novo Nordisk

    Novo, in rare deal, buys rights to Prothena amyloidosis treatment

    The Danish pharma will pay $100 million in the near term and as much as $1.2 billion overall for an antibody Prothena is developing for ATTR amyloidosis.

    By July 12, 2021
  • Image attribution tooltip
    Warren Little via Getty Images

    GSK returns to brain drugs with major biotech deal

    The pharmaceutical giant best known for its work in cancer, HIV and respiratory illnesses is now paying at least $700 million to get its hands on two experimental drugs from Alector.

    By July 2, 2021
  • Nestlé joins Seres in deal to market microbiome drug

    The health science unit at Nestlé may pay more than $500 million to secure rights in the U.S. and Canada for SER-109, a spore-filled capsule meant for patients with recurrent C. diff infections.

    By Kristin Jensen • July 1, 2021
  • Image attribution tooltip
    Nasdaq

    Deals surge, returns slip: takeaways from a record half for biotech IPOs

    Biotech initial public offerings could break records set just last year. But their average size and performance are declining, which some say might reflect an overdue correction.

    By June 30, 2021
  • Image attribution tooltip
    Getty Images

    With Alzheimer's drugs in focus, Bristol Myers rejoins the hunt

    The pharmaceutical giant is spending $80 million for an exclusive license to an experimental drug developed by Prothena.

    By June 24, 2021
  • Image attribution tooltip
    Courtesy of GSK Flickr page

    GSK outlines ambitious 10-year plan, but hits investors' near-term outlook

    Under pressure from activist investors, the British drugmaker set lofty sales targets for a "new GSK" after a planned exit from consumer health. But shareholders will first face a dividend cut.

    By June 23, 2021